ATE432080T1 - Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation - Google Patents

Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation

Info

Publication number
ATE432080T1
ATE432080T1 AT96930529T AT96930529T ATE432080T1 AT E432080 T1 ATE432080 T1 AT E432080T1 AT 96930529 T AT96930529 T AT 96930529T AT 96930529 T AT96930529 T AT 96930529T AT E432080 T1 ATE432080 T1 AT E432080T1
Authority
AT
Austria
Prior art keywords
proliferation
inhibiting
cell activation
antibodies
cd2a
Prior art date
Application number
AT96930529T
Other languages
English (en)
Inventor
Herve Bazin
Dominique Latinne
Ruth Kaplan
Thomas Kieber-Emmons
Christina Postema
Mary White-Scharf
Original Assignee
Biotransplant Inc
Univ Catholique Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotransplant Inc, Univ Catholique Louvain filed Critical Biotransplant Inc
Application granted granted Critical
Publication of ATE432080T1 publication Critical patent/ATE432080T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96930529T 1996-08-16 1996-08-16 Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation ATE432080T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/013281 WO1998007444A1 (en) 1996-08-16 1996-08-16 LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION

Publications (1)

Publication Number Publication Date
ATE432080T1 true ATE432080T1 (de) 2009-06-15

Family

ID=22255617

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96930529T ATE432080T1 (de) 1996-08-16 1996-08-16 Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation

Country Status (10)

Country Link
EP (1) EP0959899B9 (de)
JP (1) JP2001521374A (de)
AT (1) ATE432080T1 (de)
AU (1) AU737602B2 (de)
CA (1) CA2262546C (de)
DE (1) DE69637943D1 (de)
DK (1) DK0959899T3 (de)
ES (1) ES2327980T3 (de)
PT (1) PT959899E (de)
WO (1) WO1998007444A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003245752A1 (en) * 2002-06-28 2004-01-19 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
DK1534819T3 (da) 2002-08-21 2010-04-19 Revivicor Inc Griselignende dyr, som mangler enhver ekspression af funktionel alfa-1,3-galactosyltransferase
WO2005047469A2 (en) 2003-11-05 2005-05-26 University Of Pittsburgh PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
AU2005223617A1 (en) 2004-03-17 2005-09-29 Revivicor, Inc. Tissue products from animals lacking functional alpha 1,3 galactosyl transferase
JP2023531251A (ja) * 2020-06-23 2023-07-21 ゼラリオン マルタ リミテッド 抗ｃｄ２抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2700893A (en) 1952-08-06 1955-02-01 Teddy A Kudlacik Balancing device
US4798806A (en) * 1980-01-08 1989-01-17 Ortho Pharmaceutical Corporation Compositions and methods using a monoclonal antibody to a human T cell antigen
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
ES2164699T3 (es) * 1993-03-05 2002-03-01 Univ Catholique Louvain Anticuerpo lo-cd2a y usos del mismo para inhibir la activacion y la proliferacion de las celulas t.
CN113299700A (zh) 2021-05-08 2021-08-24 武汉华星光电半导体显示技术有限公司 一种显示面板及其制备方法

Also Published As

Publication number Publication date
AU6953296A (en) 1998-03-06
CA2262546C (en) 2009-03-17
WO1998007444A1 (en) 1998-02-26
HK1021318A1 (en) 2000-06-09
EP0959899B1 (de) 2009-05-27
EP0959899B9 (de) 2009-10-21
CA2262546A1 (en) 1998-02-26
DK0959899T3 (da) 2009-09-07
EP0959899A1 (de) 1999-12-01
AU737602B2 (en) 2001-08-23
PT959899E (pt) 2009-08-28
EP0959899A4 (de) 2005-01-12
DE69637943D1 (de) 2009-07-09
JP2001521374A (ja) 2001-11-06
ES2327980T3 (es) 2009-11-05

Similar Documents

Publication Publication Date Title
EP1003552A4 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGENE ZUR HEMMUNG VON T-ZELL AKTIVIERUNG UND WACHSTUM
DK0735893T3 (da) PAN DR-bindende peptider til styrkelse af immunsvaret
DK0942740T3 (da) Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
BRPI0410129A (pt) uso terapêutico de anticorpos anti-cs1
ATE407952T1 (de) Mutierte nicht aktivierende igg2 domäne und diese sequenz enthaltende anti-cd3 antikörper
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
DK0741784T3 (da) Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler
DK0859957T3 (da) Patientspecifikke immunadsorbenser til ekstraporal apherese og fremgangsmåde til deres fremstilling
ATE132197T1 (de) Monoklonale antikörper
EP0313378A3 (de) Methoden und Zusammensetzungen für vorübergehende Elimination von humoralen immunen Antikörpern
BR9306345A (pt) Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
NO973875L (no) Fremgangsmåte for stimulering av en immunrespons
DE60042941D1 (de) Verwendung von anti-cd3 monoklonale antikörper und il-5 zur behandlung von autoimmunkrankheiten
ATE432080T1 (de) Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation
DE69638145D1 (de) Verfahren zur herbeiführung einer immuntoleranz mit hilfe von immuntoxinen
Maestroni κ‐Opioid Receptors in Marrow Stroma Mediate the Hematopoietic Effects of Melatonin‐Induced Opioid Cytokinesa a
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
ATE401899T1 (de) Verwendung von gangliosiden zur prävention, hemmung und therapie von sepsis
ATE99333T1 (de) Immunogen und seine verwendung zur gewinnung von antikoerpern gegen haemoglobin a1c.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0959899

Country of ref document: EP